Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 17

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 17
---
 financial, technical
and other resources, such as larger research and development staff and well-established marketing and sales forces, and they
may operate in jurisdictions where lower standards of evidence are required to bring products to market. These competitors may succeed
in developing, acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than
Renovaro Cube’s or BioSymetrics’ products. In addition, established medical technology, biotechnology, or pharmaceutical companies
may invest heavily to accelerate the discovery and development of tests that could make Renovaro Cube’s or BioSymetrics’ products
less competitive than Renovaro anticipated.

Renovaro
Cube’s and BioSymetrics’ ability to compete successfully will depend largely on the ability of each to:

    ●
    successfully commercialize its products;

    ●
    demonstrate compelling advantages in the performance and convenience of its products, including on a cost-competitive basis;

    ●
    achieve market acceptance of its products by consumers, including self-insured employers, integrated health systems, healthcare providers and patients;

28

    ●
    achieve adequate coverage or reimbursement by third-party payors for its products;

    ●
    differentiate its product from the other tests and products of current and potential competitors;

    ●
    attract qualified scientific, data science, clinical development, product development and commercial personnel;

    ●
    obtain, maintain, defend and enforce patents and other intellectual property rights and claims as necessary for its products;

    ●
    obtain and maintain any necessary or desirable clearance or approval from regulators in Europe, the United Kingdom, the United States and other jurisdictions;

    ●
    successfully collaborate with institutions in the discovery, development and commercialization of its products; and

    ●
    successfully expand its operations and implement a successful sales and marketing strategy to support commercialization.

Renovaro
Cube and BioSymetrics may not be able to compete effectively if they are unable to accomplish one or more of these or similar objectives.

If
Renovaro Cube or BioSymetrics cannot enter new collaborations in a timely manner and on acceptable terms, their efforts to develop and
commercialize their products could be delayed or adversely affected.

From
time to time, Renovaro Cube and BioSymetrics expect to engage in discussions with potential development and/or commercial collaborators
that may or may not lead to collaborations. However, Renovaro Cube and BioSymetrics cannot guarantee that any discussions will result
in